Who Paid My Doc
Genvisc 850 Sodium Hyaluronate
Device Pain Management
PDI 00850653006016
General payments
$15,720
Research payments
$103,316
Through program year 2025, $15,720 in general payments and $103,316 in research payments were reported against Genvisc 850 Sodium Hyaluronate (Pain Management).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,883 | 83 |
| 2024 | General | $3,383 | 164 |
| 2023 | General | $6,458 | 322 |
| 2023 | Research | $103,316 | 5 |
| 2022 | General | $3,996 | 197 |
Breakdown
The top 5 of 67 recipients; each share is of general payments naming this product in 2025.
The top 5 of 23 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 13 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
766 general · 5 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.